Odonate Therapeutics Inc

Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The company's initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity reactions; and improved activity against chemotherapy-resistant tumors.
  • TickerODT
  • ISINUS6760791060
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

Jonathan Moreland

InsiderInsights Weekly Tables: June 29, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: June 28, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: June 18, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

1 director bought

A director at Odonate Therapeutics Inc bought 50,000 shares at 26.151USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

ValuEngine Rating and Forecast Report for ODT

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch